Orbell, Lai YeeAbutheraa, NoufDuncombe, Andrew S.McMullin, Mary FrancesMesa, RubenMcShane, CharleneJames, GlenAnderson, Lesley2024-02-232024-02-232023-11Orbell, L Y, Abutheraa, N, Duncombe, A S, McMullin, M F, Mesa, R, McShane, C, James, G & Anderson, L 2023, 'The JAK2V617F mutation and the role of therapeutic agents in alleviating myeloproliferative neoplasm symptom burden', European Journal of Haematology, vol. 4, no. 4, pp. 1071-1080. https://doi.org/10.1002/jha2.8050902-4441ORCID: /0000-0002-1000-3649/work/147045740ORCID: /0000-0003-2665-5630/work/189632901https://hdl.handle.net/2164/22838Funding information: MPNVoice,Grant/AwardNumber:0001 Acknowledgements: The authors would like to express gratitude to the participants who gave their time to take part in the MOSAICC pilot study. We would also like to acknowledge the work of the charity MPN Voice (grant number 0001), formerly MPD Voice, who kindly funded the work of the MOSAICC pilot study. Finally, we would like to thank Dr Barry Crouch from the University of Aberdeen Digital Research Service, whose knowledge and assistance in coding and statistical software were fundamental to the completion of this research.10701351engSDG 3 - Good Health and Well-beingessential thrombocythaemiaJanus kinase 2managementmyeloproliferative neoplasmPolycythaemia veraprimary myelofibrosistreatmentRC0254 Neoplasms. Tumors. Oncology (including Cancer)RC0254Journal article10.1002/jha2.80544